Teva Pharmaceuticals USA Inc. has initiated a recall of over 580,000 bottles of Prazosin Hydrochloride capsules due to the presence of a carcinogenic impurity. The recall affects various strengths: 1mg, 2mg, and 5mg capsules, which are commonly used to treat hypertension. The recall was first announced on October 7, 2023, and was classified as a Class II recall on October 24, 2023.
A Class II recall indicates that while the consumption of the product may lead to health problems, those issues are typically temporary or reversible. According to a Health Hazard Assessment conducted by Teva, the overall risk of harm from the recalled products is considered medium.
The Food and Drug Administration (FDA) discovered the carcinogenic impurity during routine testing, prompting the recall. Teva Pharmaceuticals, based in New Jersey, emphasized its commitment to patient safety in a statement. “Prazosin is indicated for the treatment of hypertension, to lower blood pressure, and there are many alternative treatments available to patients,” the company stated. This assurance highlights the availability of other options for individuals affected by the recall.
Patients currently taking Prazosin Hydrochloride are advised to contact their pharmacy for guidance on how to safely dispose of the affected medication. Teva has also taken steps to notify customers directly, sending recall letters with specific instructions for returning the recalled products.
In light of this significant recall, individuals who may have purchased Prazosin Hydrochloride capsules should check their medicine cabinets for the affected lot codes. The recall serves as a reminder of the importance of vigilance regarding medication safety and the role of regulatory bodies like the FDA in ensuring public health.
Teva Pharmaceuticals has reiterated its priority of maintaining high standards of safety and quality throughout the lifecycle of its products. As the situation develops, further updates may be provided to keep healthcare providers and the public informed.
